Madrigal Pharmaceuticals (MDGL)
Commercializes Rezdiffra and develops combination therapies for MASH.
$523.98
vs last close+2.02 (+0.39%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≥ 99.00% | 22.87M shares | |
|---|---|---|---|
| 439 holders · as of Jun 30, 2026 · largest filers only | |||
| Insiders | 18.93% | 4.37M shares | |
| 16 holders · as of Sep 11, 2026 | |||
| Strategic holders | 8.74% | 2.02M shares | |
| 1 holder · as of May 15, 2026 | |||
| Adds to | 126.67% | ||
23.10M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the 89 largest filers, so at least this.
These groups come from separate filings that can overlap, so they add to 126.67%; nothing is left for Other.
13F, as of Jun 30, 2026
439 holders · 22.87M shares · 79 new positions · 223 increased · 136 reduced · 44 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 2.14M | 9.28% | +1.4K | Aug 14, 2026 |
| RTW Investments, LP | 1.99M | 8.63% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 1.94M | 8.38% | +1.94Mnew | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 1.83M | 7.94% | +15.2K | Aug 14, 2026 |
| Paulson & Co. Inc. | 1.34M | 5.80% | −52.2K | Aug 14, 2026 |
| BlackRock, Inc. | 1.20M | 5.20% | −359.2K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 835.7K | 3.62% | +8.5K | Aug 13, 2026 |
| Wellington Management Group LLP | 825.7K | 3.57% | +130.8K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Roderick Wong, M.D.incl. RTW Investments, LP | 9.20% | 1.99M | 13G | Nov 14, 2024 |
| Janus Henderson Group PLC | 8.80% | 2.02M | 13G | May 15, 2026 |
| Paul A Friedman, M.D. | 7.80% | 1.81M | 13D | Dec 12, 2025 |
| Rebecca Taub, M.D. | 7.80% | 1.81M | 13D | Dec 12, 2025 |
| Paulson & Co. Inc. | 6.10% | 1.39M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 11, 2026 | William John Sibolddirector, officer: President and CEO | Sale · 10 lots | 5,221 | $542.39 | 197,746 |
| Sep 9, 2026 | William John Sibolddirector, officer: President and CEO | Sale · 14 lots | 6,362 | $535.59 | 202,967 |
| Aug 17, 2026 | Shannon T. Kelleyofficer: General Counsel | Sale | 664 | $514.97 | 11,474 |
| Jul 20, 2026 | William John Sibolddirector, officer: President and CEO | Sale · 10 lots | 2,500 | $547.30 | 209,329 |
| Jun 1, 2026 | David Soergelofficer: Chief Medical Officer | Sale | 1,042 | $495.74 | 10,033 |
| May 22, 2026 | Richard S. Levydirector | Sale · 12 lots | 5,682 | $515.44 | 22,015 |
| May 18, 2026 | David Soergelofficer: Chief Medical Officer | Sale | 844 | $515.90 | 11,075 |
| Mar 6, 2026 | Rebecca Taubdirector | Sale | 491 | $431.94 | 452,213 |
| Mar 6, 2026 | Carole Huntsmanofficer: Chief Commercial Officer | Sale | 419 | $431.94 | 12,692 |
| Mar 6, 2026 | Shannon T. Kelleyofficer: General Counsel | Sale | 360 | $431.94 | 12,138 |
House and Senate disclosures
Not reported.